Creative Planning
DMAC icon

Creative Planning’s DiaMedica Therapeutics DMAC Stock Holding History

Creative Planning’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$170K Sell
24,140
-9,459
-28% -$58.1K ﹤0.01% 3925
2026
Q1 		$227K Sell
33,599
-25,256
-43% -$200K ﹤0.01% 3645
2025
Q4 		$468K Buy
58,855
+20,065
+52% +$150K ﹤0.01% 2904
2025
Q3 		$266K Buy
+38,790
New +$210K ﹤0.01% 3240

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Creative Planning's DMAC Position: Q2 2026 in Review

Creative Planning reduced its DiaMedica Therapeutics (DMAC) stake by 28% in Q2 2026, selling an estimated $58.1K and leaving 24,140 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #3925.

Creative Planning first reported a position in DMAC in Q3 2025 and has held it in 4 quarters since. The position peaked at $468K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Creative Planning held 24,140 shares of DiaMedica Therapeutics worth $170K as of Q2 2026.
  • Creative Planning sold 9,459 DiaMedica Therapeutics shares in Q2 2026, an estimated $58.1K.
  • DiaMedica Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #3925 holding.
  • Creative Planning first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Creative Planning's DiaMedica Therapeutics position peaked at $468K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.